Lithium (Low-Dose) for Neuroprotection

Research suggests that low-dose lithium may exert meaningful neuroprotective effects through multiple biological mechanisms, including inhibition of programmed cell death, reduction of oxidative stress and inflammation, promotion of autophagy, and interference with toxic protein accumulation in the brain. The evidence base draws from narrative reviews, preclinical animal studies, and a small number of clinical investigations, with the overall direction leaning supportive but qualified — laboratory and animal findings consistently show protective effects, while human clinical data remains limited and preliminary. Studies indicate that these neuroprotective benefits may occur at blood concentrations well below those used in standard bipolar disorder treatment, with research exploring applications ranging from Alzheimer's disease and mild cognitive impairment to Parkinson's disease and stroke-related brain injury, though most clinical work in these areas is still early-stage and lacks the large, well-controlled trials needed to confirm efficacy. Limitations worth noting include the relatively small size and open-label design of existing clinical trials, the well-documented potential for toxicity even at lower doses requiring careful monitoring, and the fact that the precise mechanisms underlying low-dose effects are not yet fully understood, meaning the current evidence warrants cautious interest rather than firm conclusions.